{"schema_version":"secwatch.filing_event.v1","accession":"0001773751-25-000352","form_type":"8-K","ticker":"HIMS","cik":"0001773751","company_name":"Hims & Hers Health, Inc.","filed_at":"2025-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.390214+00:00","generated_at":"2026-05-17T00:55:17.772060+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Hims & Hers Q3 revenue $599M (+49% YoY), Adj. EBITDA $78.4M; narrows FY25 guidance","bullets":["Q3 revenue $599M (+49% YoY), net income $15.8M (prior-year $75.6M included $60.8M tax benefit)","Adj. EBITDA $78.4M (+53% YoY); subscribers 2.47M (+21% YoY); monthly online revenue per subscriber $80 (+19% YoY)","Gross margin 74% vs 79% YoY, hit by shorter shipping cadences for weight-loss offerings","FY25 revenue guidance narrowed to $2.34-2.36B, Adj. EBITDA guidance $307-317M","Entering testosterone, menopause care; discussions with Novo Nordisk for Wegovy; GRAIL investment"],"urls":{"canonical":"https://secwatch.observer/filing/0001773751-25-000352","json":"https://secwatch.observer/filing/0001773751-25-000352.json","markdown":"https://secwatch.observer/filing/0001773751-25-000352.md","text":"https://secwatch.observer/filing/0001773751-25-000352.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1773751/000177375125000352/0001773751-25-000352-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1773751/000177375125000352/hims-20251103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:55:17.772060+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}